Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer
Status:
Active, not recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a window-of-opportunity study that examines the efficacy of doxycycline, and
FDA-approved oral antibiotic, on metakaryotic (cancer stem cells) in resectable pancreatic
cancer following eight weeks of treatment.